TY  - JOUR
TI  - A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus
AB  - Objectives: Metformin is the first choice for type 2 diabetes mellitus (T2DM) treatment in the guidelines and is used in combination with many drugs. Growth arrest-specific protein 6 (Gas6)/Axl signaling plays a role in many metabolic disorders. This study aims to investigate the effects of metformin and metformin-insulin combination used in patients with T2DM on Gas6, Axl, and soluble Axl (sAxl) levels. Methods: A total of 71 patients diagnosed with T2DM and 21 healthy subjects were divided into 4 groups control, diet and exercises recommended (DER), metformin, and metformin + insulin. Diabetic patients were treated with metformin only or with a metformin-insulin combination and monitored for six months. Gas6, Axl, and sAxl levels of subjects’ sera obtained from their baseline and posttherapeutic sixth month blood samples were measured by ELISA methods. Results: Compared to baseline, the sixth month Gas6 and Axl levels of metformin and metformin + insulin groups significantly decreased (p<0.05). However, there was no statistically significant difference in sAxl values for these two groups of patients. Conclusions: The use of metformin in diabetic patients may be beneficial for inhibiting the Gas6/Axl pathway. This study presents a new aspect of the pleiotropic effects of metformin. This study will be clinically useful for designing therapeutic approaches targeting Gas6/Axl.
AU  - bayram, fahri
AU  - Atıcı, Yasemin
AU  - baskol, gulden
DO  - 10.1515/tjb-2022-0013
PY  - 2022
JO  - Türk Biyokimya Dergisi
VL  - 47
IS  - 6
SN  - 1303-829X
SP  - 775
EP  - 782
DB  - TRDizin
UR  - http://search/yayin/detay/1173749
ER  -